Know Labs Appoints Chris Somogyi as President, International
Somogyi to lead Know Labs' "Skunkworks" Program and drive global revenues. Know Labs, Inc. (NYSE:KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi
Know Labs Inc (KNW) Q2 2024 Earnings Call Transcript Highlights: Strategic Developments Amid ...
Earnings Call Summary | Know Labs(KNW.US) Q2 2024 Earnings Conference
The following is a summary of the Know Labs, Inc. (KNW) Q2 2024 Earnings Call Transcript:Financial Performance:Know Labs reported an operating loss of $4.73 million for Q2 2024, a decrease of 1.7% fro
Know Labs | 10-Q: Quarterly report
Know Labs Q2 2024 GAAP EPS $(0.07) Misses $(0.05) Estimate
Know Labs (AMEX:KNW) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 30 percent increase over losses of $(0.10) per share
Know Labs 2Q Loss/Shr 7c >KNW
Know Labs 2Q Loss/Shr 7c >KNW
Press Release: Know Labs, Inc. Reports Second Quarter FY 2024 Results
Know Labs, Inc. Reports Second Quarter FY 2024 Results SEATTLE--(BUSINESS WIRE)--May 15, 2024-- Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technolog
Know Labs to Present Clinical Research at the 2024 American Association of Clinical Endocrinology Annual Meeting
The Company's oral abstract presentation features results from its clinical study that demonstrate the accuracy and medical application of its proprietary sensor. Know Labs, Inc. (NYSE:KNW), an emerging developer of
Press Release: Know Labs, Inc. to Host Review of Second Quarter Fiscal Year 2024 Results on May 15, 2024
Know Labs, Inc. to Host Review of Second Quarter Fiscal Year 2024 Results on May 15, 2024 SEATTLE--(BUSINESS WIRE)--May 08, 2024-- Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-
Know Labs, Inc. to Host Review of Second Quarter Fiscal Year 2024 Results on May 15, 2024
SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates a
Know Labs Price Target Announced at $1.00/Share by Benchmark
Know Labs Price Target Announced at $1.00/Share by Benchmark
Know Labs Initiated at Speculative Buy by Benchmark
Know Labs Initiated at Speculative Buy by Benchmark
Know Labs (KNW.US) was first covered by Benchmark, which gave it a Speculative Buy rating, with a target price of $1.00.
Know Labs (KNW.US) was first covered by Benchmark, which gave it a Speculative Buy rating, with a target price of $1.00.
Benchmark Initiates Coverage On Know Labs With Speculative Buy Rating, Announces Price Target of $1
Benchmark analyst Bruce Jackson initiates coverage on Know Labs with a Speculative Buy rating and announces Price Target of $1.
Know Labs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/08/2024 56.01% Benchmark → $1 Initiates Coverage On → Speculative Buy
Know Labs to Present Clinical Research at the 2024 American Physiology Summit
The Company demonstrates significant progress since presenting at last year's Summit. Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been
Know Labs Reports Promising Results From Clinical Study
Know Labs' Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study
Know Labs' first study including participants with diabetes and venous blood as a comparative reference demonstrates its proprietary sensor's accuracy and medical application.SEATTLE--(BUSINESS WIRE)-
Dawson James Downgrades Know Labs Stock to Neutral, Withdraws 12-month PT
Know Labs to Raise up to $12M for Non-invasive CGM Tech
No Data